Literature DB >> 20717958

Physiological implications of adenosine receptor-mediated platelet aggregation.

Hillary A Johnston-Cox1, Dan Yang, Katya Ravid.   

Abstract

Adenosine is an important mediator of inhibition of platelet activation. This metabolite is released from various cells, as well as generated via activity of ecto-enzymes on the cell surface. Binding of adenosine to A(2) subtypes (A(2A) or A(2B)), G-protein coupled adenosine receptors, results in increased levels of intracellular cyclic adenosine monophosphate (cAMP), a strong inhibitor of platelet activation. The role and importance of adenosine and its receptors in platelet physiology are addressed in this review, including recently identified roles for the A(2B) adenosine receptor as a modulator of platelet activation through its newly described role in the control of expression of adenosine diphosphate (ADP) receptors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20717958     DOI: 10.1002/jcp.22379

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  14 in total

1.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

Review 2.  Historical perspective and future directions in platelet research.

Authors:  B S Coller
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

3.  Purinergic system ecto-enzymes participate in the thromboregulation of patients with indeterminate form of Chagas disease.

Authors:  Viviane do Carmo Gonçalves Souza; Karine B Schlemmer; Cristiano B Noal; Jeandre A S Jaques; Margarete D Bagatini; Victor C Pimentel; Luiz Felipe D Carli; Cláudio A M Leal; Juliana Fleck; Maria B Moretto; Maria R C Schetinger; Daniela B R Leal
Journal:  Purinergic Signal       Date:  2012-07-01       Impact factor: 3.765

4.  The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.

Authors:  Binggang Xiang; Guoying Zhang; Hongmei Ren; Manjula Sunkara; Andrew J Morris; T Kent Gartner; Susan S Smyth; Zhenyu Li
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240

5.  Randomized Trial Comparing the Effects of Ticagrelor Versus Clopidogrel on Myocardial Perfusion in Patients With Coronary Artery Disease.

Authors:  Matthieu Pelletier-Galarneau; Chad R R N Hunter; Kathryn J Ascah; Rob S B Beanlands; Girish Dwivedi; Robert A deKemp; Benjamin J W Chow; Terrence D Ruddy
Journal:  J Am Heart Assoc       Date:  2017-05-02       Impact factor: 5.501

6.  Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73-converted adenosine.

Authors:  P Netsch; S Elvers-Hornung; S Uhlig; H Klüter; V Huck; F Kirschhöfer; G Brenner-Weiß; K Janetzko; H Solz; P Wuchter; P Bugert; K Bieback
Journal:  Stem Cell Res Ther       Date:  2018-07-04       Impact factor: 6.832

Review 7.  A review of the effects of ticagrelor on adenosine concentration and its clinical significance.

Authors:  Mohammed Ahmed Akkaif; Mei Li Ng; Muhamad Ali Sk Abdul Kader; Nur Aizati Athirah Daud; Abubakar Sha'aban; Baharudin Ibrahim
Journal:  Pharmacol Rep       Date:  2021-07-20       Impact factor: 3.024

8.  Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis.

Authors:  Yan Hou; Naadiya Carrim; Yiming Wang; Reid C Gallant; Alexandra Marshall; Heyu Ni
Journal:  J Biomed Res       Date:  2015-10-30

9.  Ectonucleoside Triphosphate Diphosphohydrolase-1/CD39 Affects the Response to ADP of Female Rat Platelets.

Authors:  Elisabetta Caiazzo; Rossella Bilancia; Antonietta Rossi; Armando Ialenti; Carla Cicala
Journal:  Front Pharmacol       Date:  2020-01-31       Impact factor: 5.810

10.  Comparison of atrial fibrillation predictors in patients with acute coronary syndrome using ticagrelor or clopidogrel

Authors:  Engin Algül; Hamza Sunman; Muhammet Dural; İlkin Guliyev; Mert Aker; Mehmet Ali Felekoğlu; Mehmet Erat; Murat Tulmaç; Sadık Açıkel; Tolga Çimen
Journal:  Turk J Med Sci       Date:  2019-10-24       Impact factor: 0.973

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.